Skip to main content
Top
Published in: Clinical Rheumatology 8/2022

Open Access 21-03-2022 | Infliximab | Brief Report

Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry

Authors: John Tesser, Iris Lin, Natalie J. Shiff, Soumya D. Chakravarty, Gabriela Schmajuk, Nevin Hammam, Sheetal Desai

Published in: Clinical Rheumatology | Issue 8/2022

Login to get access

Abstract

Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing to differences in biologic construct, patients with IV-infliximab treatment failure may benefit from switching to IV-golimumab. Utilizing the ACR’s Rheumatology Informatics System for Effectiveness (RISE), a large electronic health records registry based in the USA, we assessed RA disease activity in patients switching from IV-infliximab to IV-golimumab. This retrospective, longitudinal, single-arm study included adults (≥ 18 years) with ≥ 1 RA diagnosis code between 2014 and 2018 and ≥ 1 IV-infliximab prescription within 6 months of a new IV-golimumab order (index date). Longitudinal assessments of disease activity using the Clinical Disease Activity Index (CDAI) were calculated in patients continuing IV-golimumab for 6–9- and 9–12-months post-switch. Paired t-tests evaluated significance of mean improvements during the follow-up periods. Most RA patients with disease activity assessments during the 6-month follow-up (N = 100; mean age: 65.3 years; 81% female; 74% white) demonstrated moderate-to-high disease activity (CDAI: 73% [38/52]) at enrollment. On average, patients showed significant improvement in disease activity within 6–9 months of switching; mean CDAI scores improved from 21.3 to 14.1 (p < 0.0001) and were durable through 9–12 months of treatment. Real-world patients with moderate-to-high disease activity who switched from IV-infliximab to IV-golimumab demonstrated significant and sustained improvements post-switch as measured by the CDAI.
Key Points
This study used real-world data from the Rheumatology Informatics System for Effectiveness (RISE) registry to evaluate the efficacy of directly switching from intravenous (IV)-infliximab to IV-golimumab to control rheumatoid arthritis (RA) disease activity.
Most IV-infliximab patients had moderate-to-high disease activity at the time of the switch.
On average, IV-golimumab was effective in improving RA disease activity after switching from IV-infliximab as measured by the Clinical Disease Activity Index.
These data suggest that real-world RA patients with persistent symptoms despite treatment with IV-infliximab may realize improved disease control with a switch to IV-golimumab.
Appendix
Available only for authorised users
Literature
6.
go back to reference Weinblatt ME, Bingham CO 3rd, Mendelsohn AM et al (2013) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 72(3):381–389. https://doi.org/10.1136/annrheumdis-2012-201411CrossRefPubMed Weinblatt ME, Bingham CO 3rd, Mendelsohn AM et al (2013) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 72(3):381–389. https://​doi.​org/​10.​1136/​annrheumdis-2012-201411CrossRefPubMed
7.
go back to reference Weinblatt ME, Westhovens R, Mendelsohn AM (2014) Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3 randomised multicentre double blind placebo controlled GO-FURTHER trial. Ann Rheum Dis 73(12):2152–2159. https://doi.org/10.1136/annrheumdis-2013-203742 Weinblatt ME, Westhovens R, Mendelsohn AM (2014) Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3 randomised multicentre double blind placebo controlled GO-FURTHER trial. Ann Rheum Dis 73(12):2152–2159. https://​doi.​org/​10.​1136/​annrheumdis-2013-203742
8.
go back to reference Bingham CO 3rd, Mendelsohn AM, Kim L et al (2015) Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III double-blind, randomized, placebo-controlled trial. Arthritis Care Res (Hoboken) 67(12):1627-1636. https://doi.org/10.1002/acr.22556CrossRef Bingham CO 3rd, Mendelsohn AM, Kim L et al (2015) Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III double-blind, randomized, placebo-controlled trial. Arthritis Care Res (Hoboken) 67(12):1627-1636. https://​doi.​org/​10.​1002/​acr.​22556CrossRef
12.
go back to reference Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177. https://doi.org/10.1136/annrheumdis-2014-205325CrossRefPubMed Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177. https://​doi.​org/​10.​1136/​annrheumdis-2014-205325CrossRefPubMed
17.
go back to reference Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35(11):2136–2147. https://doi.org/10.3899/jrheum.080182CrossRefPubMed Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35(11):2136–2147. https://​doi.​org/​10.​3899/​jrheum.​080182CrossRefPubMed
23.
24.
go back to reference Hammer HB, Uhlig T, Kvien TK, Lampa J (2018) Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 70(5):703–712. https://doi.org/10.1002/acr.23339CrossRef Hammer HB, Uhlig T, Kvien TK, Lampa J (2018) Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 70(5):703–712. https://​doi.​org/​10.​1002/​acr.​23339CrossRef
Metadata
Title
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Authors
John Tesser
Iris Lin
Natalie J. Shiff
Soumya D. Chakravarty
Gabriela Schmajuk
Nevin Hammam
Sheetal Desai
Publication date
21-03-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 8/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06116-z

Other articles of this Issue 8/2022

Clinical Rheumatology 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare